Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 plus docetaxel vs placebo plus docetaxel in PD-1/PD-L1 and platinum-failed advanced NSCLC
CTR20251831Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Jul 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started Jul 2025; status: active.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20251831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251831.